AU2002249528A1 - A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge - Google Patents
A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen spongeInfo
- Publication number
- AU2002249528A1 AU2002249528A1 AU2002249528A AU2002249528A AU2002249528A1 AU 2002249528 A1 AU2002249528 A1 AU 2002249528A1 AU 2002249528 A AU2002249528 A AU 2002249528A AU 2002249528 A AU2002249528 A AU 2002249528A AU 2002249528 A1 AU2002249528 A1 AU 2002249528A1
- Authority
- AU
- Australia
- Prior art keywords
- collagen
- sponge
- tendons
- foam
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
A METHOD OF PREPARING A COLLAGEN SPONGE, A DEVICE FOR EXTRACTING A PART OF A COLLAGEN FOAM, AND AN ELONGATED COLLAGEN SPONGE
TECHNICAL FIELD
The present invention relates to a method of preparing a collagen sponge. The collagen sponge produced according to the invention is in particular useful in surgery primarily to stop capillary bleeding. The collagen sponge may also be used as a carrier to be coated with a fibrin glue preparation. The invention also relates to a device for extracting a part of a collagen foam. The invention further relates to an elongated collagen sponge, primarily for gastrointestinal use.
BACKGROUND OF THE INVENTION
Collagen has been used as a hemostyptic agent since the late sixties. Collagen is the most frequent structural protein in all mammalians. The monomeric protein of approximately 300 kDa (tropocollagen) is covalently crosslinked at specific sites. The mature protein is therefore insoluble and forms characteristic fibrils with high tensile strength. Numerous sub-classes of collagen have been described, the most common of which is collagen type I, the main collagen type in skin, tendons bones and cornea. Collagen is a fibrous protein consisting substantially of a triple helix with a length of approximately 290 nm. Five of these triple helices (tropocollagen molecules) are staggered to form a microfibril with a diameter of approximately 3.6 nm. These microfibrils have polar and non-polar segments that are readily accessible for specific inter- and intrafibrillar interactions. Microfibrils are packed into a tetragonal lattice to form subfibrils with a diameter of about 30 nm. These subfibrils are then assembled into the collagen fibril, the basic unit of connective tissue, which has a diameter of several hundred nm and is therefore visible in a light microscope as a thin line, see reference 1. Collagen gel and collagen sponge, as produced during the manufacturing process, comprises these fibrils as the smallest units, as proved by microscopy.
Collagen may be used as a material for sealing wounds, possibly with a coating comprising a fibrin glue. Fibrin glues i.e. the combination of fibrinogen, thrombin and aprotinin have successfully been used therapeutically for many years for gluing tissues and nerves and for sealing surfaces when there is minor bleeding. One draw back of the fibrin glues has been that in case of major bleeding the glue is usually washed away before sufficient polymerisation of fibrin has occurred. To overcome this problem surgeons have manually applied liquid fibrin glues to absorbable carriers such as collagen fleece.
Despite the impressive success of these combined applications this method has not been applied on a broad scale, due to some disadvantages. The preparation is relatively cumbersome, the method requires experience and skilled personnel, and the preparation is not readily available in cases of emergency, the time for preparation being in the range of 10 to 15 min. These factors stimulated the development of an improved product resulting in the development of a fixed combination of a collagen carrier covered with a coating of solid fibrinogen, solid thrombin and solid aprotinin as disclosed in EP 0 059 265. The product disclosed in EP 0 059 265 which has been marketed under the trademark TachoComb® can be applied directly to the wound. When the coating comes into contact with aqueous fluids like blood, other body fluids or saline, the components dissolve and fibrin is formed. The product is applied to the wound with a slight pressure and collagen is tightly bound (glued) to the injured surface. Haemostasis is achieved and the wound is sealed.
Beside some blood coagulation stimulating activity, the function of collagen in TachoComb® is mainly that of a carrier which adsorbs and confers mechanical stability to the coagulation preparation with which it is coated. Other advantages of collagen, in particular in the form of a sponge, are its biodegradability, its relatively high tensile strength, even in the wet state, its high resistance against the penetration of liquids and air, and its high flexibility in the wet state.
The present invention is primarily concerned with the production of a collagen sponge which may be used as a carrier for fibrinogen, thrombin and/or aprotinin, e.g., as in TachoComb®. The collagen sponge may also be used directly, i.e. without a coating, as a bandage on topical injuries, for support of haemostasis, such as for prevention of rebleeding, for weak, diffuse bleeding from parenchymatic organs, for application on burns, skin grafts, decubitus or skin defects, or as a bandage on topical injuries.
In the prior art, a number of methods for preparing a collagen carrier have been suggested. WO 86/05811 discloses a weighted microsponge for immobilizing bioactive materials in motive bioreactor systems, the microsponge comprising a highly cross-linked collagen matrix. The highly cross-linked collagen matrix is prepared by milling a source of Type I, II or III collagen to yield fibers having a diameter on the order of 1 to 50 μm and a length no greater than 200 μm. The milled collagen is formed into a soluble collagen dissolved in a solvent, or an insoluble collagen dispersed in a solvent by admixture with a solvent, such as acetic acid, lactic acid, proprionic acid or butyric acid. In the case of a collagen dispersion, the mixing is accomplished with a high level of agitation using a blender, so as to produce microfibers of the collagen. Next, a weighting additive is blended with the collagen-liquid mixture and the composite mixture is formed into small droplets
and solidified by freezing. A number of techniques for producing small particles are disclosed. The frozen composite is vacuum freeze-dried, the combination of freezing and drying being referred to as lyophilization. The freeze-dried collagen matrix composite is treated so as to cross-link the collagen. The collagen can be cross-linked using either chemical cross-linking agents, by severe dehydration at an elevated temperature or by a combination. The collagen matrix aimed at being resistant to collagenase and other enzymatic degradation thereby making these materials particularly suitable for culturing organisms. After washing the cross-linked collagen matrix, the microsponges may be sterilized and aseptically packaged. In the weighted microsponge, the collagen matrix has an open to the surface pore structure with an average pore size in the range of from about 1 to about 150 μm, the pores of the matrix occupying from about 70 to about 98% by volume of the microsponge. The microsponge further has an average particle size of from about 100 to about 1000 μm and a specific gravity of above about 1.05. The weighting material may be metal or alloys from metal, metal oxides and ceramics.
US 5,660,857 discloses a process for preparing a composite comprising an insoluble protein matrix and an oleaginous material, which is useful as a material for surgical dressings and biomedical implants, and as a cosmetic material for application to the skin. The process of US 5,660,857 comprises the steps of mixing a protein, the oleaginous material and water to form an emulsion of the oleaginous material in an aqueous dispersion of the protein, and subsequently drying or freeze-drying the emulsion to form a film or a sponge. The insoluble fibrous protein is predominantly comprised of insoluble collagen, which may suitably be obtained from bovine skin. In one embodiment, the collagen may be swollen in lactic acid prior to use.
WO 99/13902 discloses a method for producing a meningeal tissue growth matrix comprising the step of preparing physiologically compatible collagen which is substantially free of active viruses and prions. The collagen is formed into a film, a sponge, a non-woven collagen or a felt. The collagen is obtained by a process comprising cleaning skin, tendons, ligaments or bone of fat. The material is then subjected to an enzyme treatment, whereby the collagen material is swelled. The collagen material is then further swollen with an acid solution. The collagen mixture is then homogenised. The product obtained may be a matrix provided in the form of a collagen sponge, a non-woven matrix, felt or film, or a composite of two or more of he foregoing forms. A collagen sponge can be provided by adaptation of the methods for forming collagen sponges disclosed in US 5,019,087. The sponge can be prepared by lyophilization of a collagen dispersion prepared according to WO 99/13902. The sponge density achieved is said to be about 0.1 mg/cm3 to about 120 mg/cm3. According to the disclosure of WO 99/13902, the pore size ranges from about 10 μm to • about 500 μm. Laminate type of collagen sponge and collagen film are mentioned.
US 5,618,551 relates to a non-crosslinked and potentially crosslinkable pepsintreated collagen or gelatin powder modified by oxidative cleavage in an aqueous solution, which is soluble at an acid pH and stable on storage at a temperature of below 0°C for at least one month. The patent further relates to a process of preparing the powder, comprising preparing an acidic solution of pepsin-treated collagen, subjecting the acidic aqueous solution at room temperature to controlled oxidation, precipitating the oxidized and noncrosslinked pepsintreated collagen at an acid pH, and isolating, concentrating and dehydrating the noncrosslinked pepsintreated collaged so as to obtain it in the form of a reactive acidic powder, and freezing and storing the obtained reactive acidic powder at a temperature of below 0°C.
GB 1 292 326 discloses a method and apparatus for the preparation of collagen dispersions with a view to their applications, wherein a suspension of collagen fibres is prepared and subsequently introduced into a treatment chamber with stirring means. A sub-atmospheric pressure exists in the treatment chamber, in which the suspension is transformed into a dispersion by stirring and controlled acidification by means of a mineral or organic acid. According to the disclosure of GB 1 292 326, the preparation of spongy collagenic articles can be effected from dispersion or gels of collagen. In this context the documents refers to lyophilization and to dispersion or gels very rich in air bubbles. GB 1 292 326 further mentions a problem of controlling the introduction or the elimination of air bubbles in a satisfactory manner. The documents discloses, in two examples, a collagenic dispersion free of air bubbles with a collagen content of 2.5%, and an aerated dispersion of collagen with a collagen concentration of 2.5%, respectively.
Chemical Abstracts, Columbus Ohio, US, Vol. 98 13 June 1983 No. 24 mentions a collagen obtained from animal tissues such as skin or tendon bone which has been submitted to acid treatment. The collagen is reaggregated by dialysis, during which process a net of highly birefringent crystal fibres is formed. The collagen can be shaped into 0.5 mm - 2 cm sheets, or be mixed with air to form sponges, or be dispersed as a cream.
DESCRIPTION OF THE INVENTION
It has been found that the successful coating of a collagen sponge with a fibrin glue preparation depends on the texture of the collagen sponge. It is thus an object of the present invention to provide a method of producing a collagen sponge with a certain texture, in particular with the aim of making the collagen sponge suitable for coating with a fibrin glue preparation, so as to obtain a material for healing and sealing wounds. It is a further object of the invention to provide a method of producing a collagen sponge having
improved physical characteristics in relation to prior art sponges, in the sense of improved humidity, elasticity, density and elasticity module. It is a further object of the invention to provide a method for preparing a collagen sponge which is air and liquid tight in the sense that, once the collagen sponge is applied to a wound, it will not allow air or liquid to soak through the collagen sponge. It is a still further object of the invention to provide a wound closing material which can be used in gastrointestinal funnels or trachea.
Thus, in a first aspect the invention provides a method of preparing a collagen sponge, comprising the steps of: - preparing a collagen gel,
- mixing air into the collagen gel, so as to obtain a collagen foam,
- drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or having a chamber diameter average of at most 3 mm.
In the present context, the term "chamber diameter" should be understood as the largest straight-line wall-to-wall distance in a chamber, i.e. as the largest diagonal straight-line distance of a chamber. The chambers may be of a polygonal shape, such as of an octagonal shape.
It has been found that a chamber diameter of more than 0J5 mm and less than 4 mm, or a chamber diameter average of at most 3 mm, renders the collagen sponge particularly useful for being coated with a fibrin glue preparation. Preferably, the collagen gel has a dry mass in the range of 2-20 mg dry mass per 1 g gel, such as 4-18 mg, such as 5-13 mg, such as 6-11 mg per 1 g gel. The dynamic viscosity of the collagen gel is preferably 2-20 Ncm, such as 4-10 Ncm, such as 6-8 Ncm. The collagen sponge preferably has a water content of not more than 20%, such as 10-15%, such as about 18%. The elasticity module of the collagen sponge is preferably in the range of 5-100 N/cm, such as 10-50 N/cm, and the density of the sponge is preferably 1-10 mg/cm3, such as 2-7 mg/cm3.
It has been found that a collagen sponge prepared by the method according to the invention is air and liquid tight in the sense that, once the collagen sponge is applied to a wound, it will not allow air or liquid to pass through the collagen sponge. Liquids are absorbed in the sponge. This effect is primarily achieved due to the fact that the step of mixing air into the collagen gel provides a collagen sponge which has a three-dimensional structure with stacked chambers separated and substantially totally enclosed by walls of
collagen material, in contradiction to those known collagen sponges which have a fibre structure.
The collagen gel may comprise material of different types, such as type I, II or III from mammalian, transgenic or recombinant sources, but all other types of collagen can be used. The collagen may comprise material from tendons selected from the group consisting of equine tendons, human tendons, and bovine tendons. The collagen gel may additionally or alternatively comprise recombinant collagen material.
The collagen content of the isolated parts of sponge is preferably 50% - 100% related to dry mass of the sponge, such as 75% - 100%, such as 80% - 100%, such as 85% - 100%, such as 90% - 100%, such as 92 - 100%, such as 92 - 98%, such as 93 - 97%, such as 94% - 96%.
The step of preparing the collagen gel preferably comprises the steps of:
- storing the tendons at a temperature between -10°C and -30°C, and peeling the tendons,
- removing foreign protein from the tendons,
- reducing germ content in the tendons, - swelling the tendons,
- homogenising the swelled tendons.
The steps of storing, peeling, removing protein, reducing of germ content, and swelling aim at purifying the raw material, whereas the step of homogenising aims at obtaining the collagen in the form of a gel.
The step of reducing of germ content preferably comprises adding an acid, such as an organic acid, such as lactic acid to the tendons. Further, an organic solvent, such as an alcohol, such as ethanol is preferably added to the tendons. Further, the step of swelling of the tendons preferably comprises adding lactic acid to the tendons. The lactic acid used may be a 0.40 - 0.50% lactic acid, such as a 0.45% lactic acid.
The step of swelling of the tendons may comprise storing the tendons at a temperature of 4°C to 25°C, such as a temperature of 10°C to 20°C, for a period of 48 to 200 hours, such as a period of 100 to 200 hours.
The step of homogenising the swelled tendons is preferably carried out so as to obtain a particle size of collagen gel fragments, i.e. fibre balls, with a diameter of 0.8 - 1.2 cm, such as approximately 1 cm. Further, the physical characteristics of the collagen gel are
preferably as stated above. The appropriate characteristics may for example be achieved by performing the step of homogenising the swelled tendons by means of a toothed disk mill or adequate homogenisation equipment.
5 The step of mixing air into the collagen gel preferably comprises the steps of:
- mixing ambient air into the gel by means of a mixer so as to generate a collagen foam,
- feeding the mixed gel foam into a fractionising channel,
- separating collagen gel and collagen foam contained in the fractionising channel.
10 At least some of the collagen gel separated from the collagen foam in the fractionising channel may be led back to the mixer. In that case, the ratio between the amount of collagen gel which is led back to the mixer from the fractionising channel and the amount of fresh collagen gel led to the mixer is preferably between 0.1 and 0.5. The step of separating collagen gel and collagen foam preferably comprises the steps of:
15 - separating a selected part of the collagen foam contained in the fractionising channel,
- leading the selected part of the collagen foam out of the fractionising channel for drying thereof.
In a preferred embodiment of the method, a temperature of 15°C to 40°C, such as 20°C to 20 25°C is maintained in the fractionising channel.
Subsequent to mixing air into the collagen gel, the collagen foam may be homogenised for a period of 2 to 4 minutes.
25 Prior to the step of drying the collagen foam and subsequent to the step of mixing air into the collagen get, a neutraliser may be added to the collagen foam, and the collagen foam is preferably neutralised in order to arrive from a pH-value of, usually, between 2.5 and 3.5 to a pH-value in the collagen foam between 6.5 and 8.5. A neutraliser comprising an ammonia solution may be used, and the collagen foam is preferably neutralised for a
30 period of 5-30 hours, such as 10-20 hours, such as approximately 24 hours.
Prior to the step of drying the collagen foam, the collagen foam is preferably filled into a drying container in such a way that substantially no air is drawn into the foam while filling.
35 The step of drying preferably comprises drying at a temperature between 15°C and 60°C, such as between 20° and 40°C, for a period of 50-200 hours, such as 100-150 hours, so as to obtain a dry collagen sponge. The drying may be performed at a pressure slightly under atmospheric pressure, such as at a pressure of between 700 and 900 mbar, such as approximately 800 mbar.
The collagen sponge produced by the method according to the invention preferably fulfils at least one of the following criteria:
- pH-value between 5.0 and 6.0, - lactic acid content at the most 5%,
- ammonium content at the most 0.5%,
- soluble protein content, calculated as albumin content, at the most 0.5%,
- sulphate ashes content at the most 1.0%,
- heavy metal content at the most 20 ppm, - microbiological purity, at the most 103 CFU/g,
- collagen content of 75% to 100%,
- density of 1-10 mg/cm3, such as 2-7 mg/cm3,
- elasticity module of 5-100 N/cm, such as 10-50 N/cm.
The step of isolating parts of collagen sponge may comprise dividing the collagen sponge into a plurality of parts by cutting. The parts obtained may be shaped in any desirable form, such as conical, cylindrical, including cylindrical with an annular cross-section, rectangular, polygonal, cubic, and flat sheets or they may be transformed into a granulate by an appropriate granulating method etc.
In a second aspect, the present invention relates to a method of preparing a collagen sponge, comprising the steps of:
- preparing a collagen gel,
- mixing air into the collagen gel, so as to obtain a collagen foam, - drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge having the following properties:
- elasticity module in the range of 5 to 100 N/cm, - density in the range of 1 to 10 mg/cm3,
- chamber diameter of more than 0J5 mm and less than 4 mm, or a chamber diameter average of at most 3 mm.
It should be understood that any and all steps of the method according to the first aspect of the invention may also be performed in the method according to the second aspect of the invention. Further, any and all characteristics and features of the collagen sponge produced by the method according to the first aspect of the invention may also be achieved by the method according to the second aspect of the invention.
In a third aspect, the present invention provides a device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel, comprising:
- a fractionising channel comprising an inlet for receiving a flow of collagen foam, an outlet for a part of the flow of collagen foam, and a bottom portion which is inclined downwards in the direction of the flow of collagen foam,
- at least one outlet for collagen gel at the bottom portion of the fractionising channel, wherein the position of the outlet is movable in a vertical direction at an end of the fractionising channel.
In a fourth aspect, the present invention provides an elongated collagen sponge having a through-going hole or bore and a flexible wall. In a preferred embodiment, such a collagen sponge may be used closing wounds or re-establishing gastrointestinal funnel and trachea walls in mammalians. Thus, the collagen sponge may have circular or elliptical cross- section. The collagen sponge may be applied both as a filling, or as in a gastrointestinal funnel, or as an outer sleeve applied to an outer surface of a gastrointestinal funnel.
The inner diameter of the through-going hole or bore may, for application in various human gastrointestinal funnels and trachea, for example be as follows:
Bowels: 0.5 - 6 cm Rectum: 1 - 4 cm
Large intestine: 2 - 6 cm
Small intestine: 0.5 - 3 cm
Oesophagus: 0.5 - 2 cm
Trachea : 1 - 4 cm
The collagen sponge may, e.g., be used for closing wounds after surgical removal of outpouchings on gastrointestinal funnel walls, such as after rectal surgery, such as after surgical removal of hemorrhoids. Examples of indications made possible by the collagen sponge according to the invention are: - wound dressing,
- support of haemostasis, such as
- weak, diffuse bleeding from parenchymatic organs,
- surgical procedures on surgery locations where ectrosurgery or ligation has been performed prior to application of the collagen sponge, - prevention of rebleeding (securing of sutures),
- application on burns,
- bandage on topical injuries,
- drug delivery, such as delivery of antibiotics.
BRIEF DESCRIPTION OF THE DRAWINGS
Figs. 1 and 2 contain a flow chart illustrating the steps involved in a preferred embodiment of the method according to the invention,
Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. Klinik Erlangen, Germany), and
Fig. 4 discloses a stirring device for obtaining a measure of the viscosity of a collagen gel.
DESCRIPTION OF THE DRAWINGS
In a preferred embodiment, the invention comprises the following steps as illustrated in Figs. 1 and 2:
Step 1 Delivery of deep-frozen horse tendons
The horse tendons are delivered and stored at -18 °C to -25 °C.
Step 2 Peeling of horse tendons
In a half-frozen state, the thin skin of the tendons is manually or mechanically removed with a knife. The tendons are then again deep-frozen at -18 °C to -25 °C.
Step 3 Mechanical slicing of peeled horse tendons
Optionally, peeled frozen tendons are disinfected for 30 min in 70 % ethanol and passed into production rooms under ethanol. The tendons are then washed, and after washing the tendons are compacted to blocks and deep frozen at -18 °C to -25 °C. The frozen tendon blocks are then sliced with a cutting machine with a rotating knife into slices having a thickness of approximately 1 mm.
Step 4 Washing and disinfection of the tendon slices
In order to remove soluble proteins, the tendon slices are first soaked in water for injection for 3 - 6 hours, then washed with water for injection or demineralized water or salt solutions containing Ca2+ and/or Mg2+-ion within the range of 1-lOmM until the supernatant is free of hemoglobin. The tendon slices are then disinfected in 70 % ethanol for 15 min and washed twice in 0.45 % lactic acid in drinking water (sterile filtered and
depyrogenised) to remove the ethanol.
Step 5 Production of collagen pel
The washed tendon slices are soaked in 0.45 % lactic acid for 2-5 days, preferably 4 days, and then homogenised to a collagen gel. Exposure to 0.45 % lactic acid is considered to be one of the main virus inactivation steps.
Step 6 Foaming
With dissolver stirrers sterile filtered air is whipped into the collagen gel. The arising foam is fractioned, and the fraction with a bubble size of 1 - 3 mm is collected. The foam is poured from the steel container into a barrel which is slowly rotated for approximately 3 minutes to obtain a homogeneous foam. This foam is filled into drying containers. The base of the container consists of a textile tissue which is permeable to fluids, so as to allow draining of the foam. After 5 - 24 hours, preferably 18-24 hours, the drained foam is exposed to ammonia gas e.g generated from a 26 % ammonia solution of DAB quality. During this process, the surplus of ammonia shifts the pH of the foam to the alkaline region. Ammonia is removed during the subsequent drying process resulting in a neutral product.
Step 7 Drying the foam
The foam is dried in warm air in a high grade steel drying chamber for 48 - 150 hours, preferably 120 - 150 hours. The result is collagen sponge shaped in blocks.
Step 8 Cutting the collagen blocks
Blocks, also referred to as sheets, of collagen may for example be used as carriers for a coating. The cutting is performed with a vertical cutting machine. First, the sides of the block are cut off to yield a block with vertical sides with a side length of 50 cm. This block is then cut vertically into 4 bars with a width of 11 cm. The bars are again trimmed at their upper and their lower side and then sliced into strips with dimensions of 50 x 11 x 0.4 - 0.7 cm. The weight of the collagen sponge strips preferably takes into account any specification of collagen in the final product to be achieved, such as TachoComb® H, TachoComb® and Tachotop®.
Step 9 Sorting the collagen sponge strips
The collagen sponge strips are then subjected to a visual control. Strips with one or more of the following defects are discarded:
- strips with an average chamber diameter smaller than 1 mm or larger than 3 mm
- strips with inhomogeneous chamber structure - strips with holes (single chambers with a depth larger than the thickness of the sponge)
The sorted strips are stored for maximally 1 year in disinfected light metal containers at a temperature of 15 - 25 °C.
Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention, the photography being taken at a magnification factor of approximately 20,000 (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. Klinik Erlangen, Germany). The surface shown in the photography of Fig. 3 is a surface of a cross-sectional cut in a collagen sponge prepared by a method according to the present invention. The dark areas in the photography represent chambers, while the light areas in the photography represent collagen material, including walls of collagen material separating the chambers.
Fig. 4 shows a stirring device for obtaining a measure of a viscosity of a liquid, comprising a container adapted to accommodate a liquid and means for stirring said liquid. The stirring means comprise a rod attached to a fork shaped element. A liquid in the container is stirred by applying a torque to the rod, resulting in a rotational movement of the fork shaped element. The fork shaped element comprises a primary part 41 to which the rod is attached and a first and a second secondary part 42. The secondary parts are attached to the ends of the primary part As the fork shaped element rotates the surfaces moves the liquid and thus stirs the liquid.
In one embodiment the device has the following dimensions. The container is 110 mm high and 146 mm wide. The rod is 220 mm high and has a diameter of 10 mm. The primary part 41 of the fork is 90 mm long and 30 mm high. The secondary parts 42 are 90 mm high and 30 mm wide. The distance from an outer edge of the secondary parts 42 to an inner surface of the container is 28 mm.
Example I
Table I below shows parameter values of three different cycles of the method according to the invention.
Table I
Table II below shows parameter values of three different collagen sponges obtained by the method according to the invention.
Table II
Example II
This example relates to the indirect measurement of the viscosity of the collagen gel by torque measurement.
The equipment used for the torque measurement is:
- Stirring machine: EUROSTAR POWER control-vise
- Windows-Software: IKASOFT dc
- Torque indicator: VISCOKLICK VK 1
- Datalogger DC 2 - Special stirrer construction ("fork") with defined dimensions, cf. Fig. 4
- Funnel with an inner diameter of 14.6 cm and a height of 20.5 cm
- Thermometer
- Balance
An amount of 1500 g of collagen gel is filled into the funnel. The temperature of the sample is 23°C. The "fork" stirrer is fixed in the centre of the funnel. Then measurement is started. The Torque indicator is transforming the resistance of the stirrer into a value (Ncm) representing the dynamic gel viscosity.
In order to verify the measurement of the torque, a standard solution of 59% Polyethylenglycol is prepared. Viscosity of this solution is measured by a Haake Visosimeter RV 20 Rotovisko. The dynamical viscosity η of this solution is in the range of η = 925 ± 25 mPas at 23°C. This solution viscosity is measured by the above gel measuring equipment, and the torque value thereby measured should be in the range of 3.66 Ncm ± 5% at 23°C.
REFERENCES
1. Baer, E. Gathercole, L.J. and Keller, A., Structure hierarchies in tendon collagen: an interim summary, Proc. Colston Conf., 1974, 189; Hiltner, A. Cassidy, J.J. and Baer, E., Mechanical properties of biological polymers, Ann. Rev. Mater. Sci., 15, 455, 1985)
Claims (41)
1. A method of preparing a collagen sponge, comprising the steps of:
- preparing a collagen gel, - mixing air into the collagen gel, so as to obtain a collagen foam,
- drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or parts with an average chamber diagonal dimension of 3 mm.
2. A method according to claim 1, wherein the collagen content of the isolated parts of sponge is 50 to 100%.
3. A method according to claim 2 or 3, wherein the collagen gel comprises collagen material of different types from at least one of the following sources: mammalian, transgenic and recombinant sources.
4. A method according to claim 3, wherein the collagen comprises material from tendons selected from the group consisting of equine tendons, bovine tendons and human tendons.
5. A method according to claim 3 or 4, wherein the step of preparing the collagen gel comprises the steps of:
- storing the tendons at a temperature between -10°C and -30°C, and peeling the tendons,
- removing foreign protein from the tendons,
- reducing germ content in the tendons,
- swelling the tendons,
- homogenising the swelled tendons.
6. A method according to claim 5, wherein the step of reducing germ content comprises adding an acid and an organic solvent to the tendons.
7. A method according to claim 6, wherein acid is an organic acid, such as lactic acid.
8. A method according to claim 6 or 7, wherein the organic solvent is an alcohol, such as ethanol.
9. A method according to any of claims 5-8, wherein the step of swelling the tendons comprises adding lactic acid to the tendons.
10. A method according to any of claims 5-9, wherein the acid has a pH value in the range 5 of 1 to 4, such as 1.5 to 3.5, such as 2.5 to 3.0.
11. A method according to any of claims 5-10, wherein the lactic acid is a 0.45% lactic acid.
10 12. A method according to any of claims 5-11, wherein the step of swelling the tendons comprises storing the tendons at a temperature of 4°C to 25°C for a period of 48 to 200 hours.
13. A method according to claim 12, wherein the tendons are stored for a period of 100 to 15 120 hours.
14. A method according to any of claims 5-13, wherein the step of homogenising the swelled tendons comprises obtaining a substance comprising particles of tendons, the particles having a length or diameter of 0.8 to 1.2 cm.
20
15. A method according to any of claims 5-14, wherein the step of homogenising the swelled tendons comprises obtaining a substance having a viscosity of 2 to 20 Ncm.
16. A method according to any of claims 5-15, wherein the step of homogenising the 5 swelled tendons is carried out by means of a toothed disk mill or comparable equipment
17. A method according to any of the preceding claims, wherein the collagen gel has a dynamic viscosity of 2-20 Ncm.
0 18. A method according to any of the preceding claims, wherein the step of mixing air into the collagen gel comprises the steps of:
- mixing ambient air into the gel by means of a mixer so as to generate a collagen foam,
- feeding the mixed gel foam into a fractionising channel,
- separating collagen gel and collagen foam contained in the fractionising channel. 5
19. A method according to claim 18, wherein at least some of the collagen gel separated from the collagen foam in the fractionising channel is led back to the mixer.
20. A method according to claim 19, wherein the ratio between the amount of collagen gel which is led back to the mixer from the fractionising channel and the amount of fresh collagen gel led to the mixer is between 0.1 and 0.5.
21. A method according to any of claims 18-20, wherein the step of separating collagen gel and collagen foam comprises the steps of:
- separating a selected part of the collagen foam contained in the fractionising channel,
- leading the selected part of the collagen foam out of the fractionising channel for drying thereof.
22. A method according to any of claims 18-21, further comprising maintaining a temperature between 15°C and 40°C in the fractionising channel.
23. A method according to any of the preceding claims, further comprising, subsequent to mixing air into the collagen gel, homogenising the collagen foam for a period of 2 to 4 minutes.
24. A method according to any of the preceding claims, further comprising, prior to the step of drying the collagen foam and subsequent to the step of mixing air into the collagen gel, adding a neutraliser to the collagen foam and neutralising the collagen foam in order to achieve a pH-value in the collagen foam between 6.5 and 8.5.
25. A method according to claim 24, wherein the neutraliser comprises an ammonia solution.
26. A method according to claim 24 or 25, wherein the collagen foam is neutralised for a period of 5-30 hours.
27. A method according to claim 26, wherein the collagen foam is neutralised for a period of 20-30 hours.
28. A method according to any of the preceding claims, wherein the step of drying comprises drying at a temperature between 15°C and 60°C for a period of 48-200 hours, so as to obtain a dry collagen sponge.
29. A method according to claim 28, wherein the step of drying is carried out at a pressure of 700 to 900 mbar.
30. A method according to any of the preceding claims, wherein the step of drying comprises drying at a temperature between 15°C and 40°C for a period of 100-200 hours.
31. A method according to any of the preceding claims, wherein the collagen sponge fulfils 5 at least one of the following criteria:
- pH-value between 5.0 and 6.0,
- lactic acid content at the most 5%,
- ammonium content at the most 0.5%,
- soluble protein content, calculated as albumin content, at the most 0.5%, 10 - sulphate ashes content at the most 1.0%,
- heavy metal content at the most 20 ppm,
- microbiological purity, at the most 103 CFU/g,
- collagen content of 75 to 100%,
- density of 1 to 10 mg/cm3,
15 - elasticity module in the range of 5-100 N/cm.
32. A method according to any of the preceding claims, wherein the collagen sponge has a water content of not more than 20%.
20 33. A method according to any of the preceding claims, wherein the step of isolating parts of collagen sponge comprises dividing the collagen sponge into a plurality of parts by cutting.
34. A method of preparing a collagen sponge, comprising the steps of: 25 - preparing a collagen gel,
- mixing air into the collagen gel, so as to obtain a collagen foam,
- drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge having the following 0 properties:
- elasticity module in the range of 5 to 100 N/cm,
- density in the range of 1 to 10 mg/cm3,
- chamber diameter of more than 0.75 mm and less than 4 mm, or a chamber diameter average of at most 3 mm. 5
35. A method according to claim 34, comprising the steps of any of claims 1-33.
36. A device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel, comprising: - a fractionising channel comprising an inlet for receiving a flow of collagen foam, an outlet for a part of the flow of collagen foam, and a bottom portion which is inclined downwards in the direction of the flow of collagen foam,
- at least one outlet for collagen gel at the bottom portion of the fractionising channel, 5 wherein the position of the outlet is movable in a vertical direction at an end of the fractionising channel.
37. An elongated collagen sponge having a through-going hole or bore and a flexible wall.
10 38. An elongated collagen sponge according to claim 37 and having a circular or elliptical cross-section.
39. An elongated collagen sponge according to claim 37 or 38, and having outer dimensions allowing the sponge to be used for closing wounds or re-establishing walls in a
15 mammalian gastrointestinal funnel or trachea system.
40. An elongated collagen sponge according to any of claims 37-39, wherein the bore or hole has diagonal dimensions corresponding to the inner or outer cross-sectional dimensions of mammalian gastrointestinal funnels or tracheas. 0
41. An elongated collagen sponge according to claim 39 or 40 having outer dimensions corresponding to the inner dimension of the human rectum, so as to make the sponge suitable for closing wounds in the rectum wall or re-establishing the rectum wall.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100135 | 2001-01-25 | ||
| DKPA200100235 | 2001-02-13 | ||
| DKPA200100135 | 2001-02-13 | ||
| DKPA200100235 | 2001-02-13 | ||
| PCT/IB2002/001452 WO2002070594A2 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002249528A1 true AU2002249528A1 (en) | 2003-03-13 |
| AU2002249528B2 AU2002249528B2 (en) | 2007-03-29 |
Family
ID=26068956
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002249528A Expired AU2002249528B2 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| AU2002255220A Active 2027-01-25 AU2002255220B2 (en) | 2001-01-25 | 2002-01-25 | Carrier with solid fibrinogen and solid thrombin |
| AU2002307809A Expired AU2002307809B2 (en) | 2001-01-25 | 2002-01-25 | A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002255220A Active 2027-01-25 AU2002255220B2 (en) | 2001-01-25 | 2002-01-25 | Carrier with solid fibrinogen and solid thrombin |
| AU2002307809A Expired AU2002307809B2 (en) | 2001-01-25 | 2002-01-25 | A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
Country Status (37)
| Country | Link |
|---|---|
| EP (4) | EP1359947A2 (en) |
| JP (4) | JP4535678B2 (en) |
| KR (2) | KR100830294B1 (en) |
| CN (3) | CN1246047C (en) |
| AR (3) | AR032400A1 (en) |
| AT (2) | ATE310044T1 (en) |
| AU (3) | AU2002249528B2 (en) |
| BG (3) | BG66420B1 (en) |
| BR (3) | BRPI0206708B8 (en) |
| CA (3) | CA2434964C (en) |
| CL (1) | CL2015003111A1 (en) |
| CR (1) | CR7034A (en) |
| CZ (3) | CZ305120B6 (en) |
| DE (2) | DE60203364T2 (en) |
| DK (2) | DK1343542T3 (en) |
| EA (4) | EA005697B1 (en) |
| EE (3) | EE05587B1 (en) |
| EG (2) | EG26417A (en) |
| ES (2) | ES2238569T3 (en) |
| HK (2) | HK1058319A1 (en) |
| HR (1) | HRP20030648B1 (en) |
| HU (3) | HU228810B1 (en) |
| IL (6) | IL157097A0 (en) |
| IS (1) | IS6885A (en) |
| ME (1) | ME00587B (en) |
| MX (3) | MXPA03006687A (en) |
| NO (3) | NO327386B1 (en) |
| NZ (3) | NZ527167A (en) |
| PL (3) | PL205181B1 (en) |
| PT (1) | PT1343542E (en) |
| RS (1) | RS50866B (en) |
| SI (2) | SI1343542T1 (en) |
| SK (3) | SK10342003A3 (en) |
| TW (2) | TWI237573B (en) |
| UA (1) | UA73028C2 (en) |
| UY (1) | UY27136A1 (en) |
| WO (3) | WO2002058749A2 (en) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020131933A1 (en) * | 1996-01-16 | 2002-09-19 | Yves Delmotte | Biopolymer membrane and methods for its preparation |
| US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
| US7435425B2 (en) | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
| US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
| US7252837B2 (en) | 2002-06-28 | 2007-08-07 | Ethicon, Inc. | Hemostatic wound dressing and method of making same |
| US7279177B2 (en) | 2002-06-28 | 2007-10-09 | Ethicon, Inc. | Hemostatic wound dressings and methods of making same |
| WO2004041254A1 (en) * | 2002-11-04 | 2004-05-21 | Nycomed Danmark Aps | Coating of a particulate material with an organic solvent-based coating composition |
| JP4769578B2 (en) * | 2003-01-20 | 2011-09-07 | 一般財団法人化学及血清療法研究所 | Hemostasis material |
| JP2006523113A (en) | 2003-04-04 | 2006-10-12 | ティシュームド リミテッド | Tissue adhesive composition |
| US8834864B2 (en) * | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
| US20040265371A1 (en) | 2003-06-25 | 2004-12-30 | Looney Dwayne Lee | Hemostatic devices and methods of making same |
| US7927626B2 (en) | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| US7186684B2 (en) * | 2003-08-07 | 2007-03-06 | Ethicon, Inc. | Hemostatic device containing a protein precipitate |
| EP1793873B1 (en) | 2004-08-03 | 2013-08-07 | Tissuemed Limited | Tissue-adhesive materials |
| US9358318B2 (en) | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
| EP2345430B1 (en) | 2004-10-20 | 2015-11-25 | Ethicon, Inc. | A reinforced absorbable multilayered fabric for use in medical devices and method of manufacture |
| EP2837393A1 (en) | 2004-10-20 | 2015-02-18 | Ethicon, Inc. | Absorbable hemostat |
| KR20060040329A (en) * | 2004-11-05 | 2006-05-10 | 나건 | Hemostatic agent which can be applied via endoscope and applying method of the same |
| KR20100102750A (en) | 2005-04-25 | 2010-09-24 | 메사추세츠 인스티튜트 오브 테크놀로지 | Compositions and methods for promoting hemostasis and other physiological activities |
| JP4864348B2 (en) * | 2005-05-27 | 2012-02-01 | 川澄化学工業株式会社 | Nerve regeneration tube |
| EP1979018B1 (en) | 2006-02-03 | 2013-08-07 | Tissuemed Limited | Tissue-adhesive materials |
| CA2640560C (en) | 2006-02-14 | 2017-07-11 | Commonwealth Scientific And Industrial Research Organisation | Joining and/or sealing tissues through photo-activated cross-linking of matrix proteins |
| HUE037994T2 (en) | 2006-04-25 | 2018-09-28 | Massachusetts Inst Technology | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions |
| BRPI0712088B8 (en) | 2006-05-31 | 2021-06-22 | Baxter Healthcare Sa | use of a non-porous, fluid-tight, multi-layered, microscopic collagen lamina biomatrix |
| TWI436793B (en) | 2006-08-02 | 2014-05-11 | Baxter Int | Rapidly acting dry sealant and methods for use and manufacture |
| WO2008019129A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
| GB0623607D0 (en) * | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
| CN101053679B (en) * | 2007-04-17 | 2010-05-26 | 浙江大学 | Method for preparing polymer multiporous holder filled with fiber protein gel |
| DE102007037056A1 (en) | 2007-07-24 | 2009-01-29 | Aesculap Ag | Hemostyptic made of freeze-dried collagen, useful e.g. to increase absorption capacity of liquids, preferably blood and treat blood vessel leakage, comprises a water-soluble biocompatible organic acid, preferably hydroxyl carboxylic acid |
| DE102007037053A1 (en) | 2007-07-24 | 2009-01-29 | Aesculap Ag | Hemostatic for minimally invasive surgery |
| DE102007045066A1 (en) | 2007-09-20 | 2009-04-02 | Mike Ehrlich | Hemostatic material containing synthetic peptides or polysaccharides |
| DE102007000574A1 (en) | 2007-10-25 | 2009-04-30 | FILK Forschungsinstitut für Leder- und Kunstbahnen gGmbH | Biologically absorbable sponge material, useful in medicine, pharmacy, cosmetics and food area, comprises a collagen-gelatin-mixture or collagen-gelatin-mixture with additives, preferably softener and/or a substance |
| CA2703103C (en) | 2007-10-30 | 2017-05-09 | Baxter Healthcare S.A. | Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects |
| CN101214391B (en) * | 2007-12-27 | 2010-05-19 | 广州倍绣生物技术有限公司 | High-efficiency biogum sealant and uses thereof |
| EP2259803B2 (en) | 2008-02-29 | 2019-03-13 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| WO2010002435A2 (en) * | 2008-07-03 | 2010-01-07 | Kulinets Irina B | Hemostatic pouch and method to stabilize hemostatic components |
| WO2010041636A1 (en) | 2008-10-06 | 2010-04-15 | 株式会社スリー・ディー・マトリックス | Tissue plug |
| US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
| CN102802683B (en) | 2009-06-16 | 2015-11-25 | 巴克斯特国际公司 | Sthptic sponge |
| EP2477617B1 (en) | 2009-09-18 | 2018-01-31 | Bioinspire Technologies Inc. | Free-standing biodegradable patch |
| US9271925B2 (en) | 2013-03-11 | 2016-03-01 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
| WO2011072482A1 (en) | 2009-12-14 | 2011-06-23 | The University Of Hong Kong | Nano cancer barrier device(ncbd) to immobilize and inhibit the division of metastic cancer stem cells |
| US8771258B2 (en) | 2009-12-16 | 2014-07-08 | Baxter International Inc. | Hemostatic sponge |
| RU2556960C2 (en) * | 2010-01-28 | 2015-07-20 | Омрикс Биофармасьютикалс Лтд. | Method of providing improved sealing by means of fibrin |
| SA111320355B1 (en) | 2010-04-07 | 2015-01-08 | Baxter Heathcare S A | Hemostatic sponge |
| BR112012030455B1 (en) | 2010-06-01 | 2021-08-17 | Baxter Healthcare S.A. | PROCESS TO MANUFACTURE A DRY AND STABLE HEMOSTATIC COMPOSITION, FINAL FINISHED CONTAINER, AND KIT TO MANAGE A HEMOSTATIC COMPOSITION |
| JP6289096B2 (en) | 2010-06-01 | 2018-03-07 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | Process for making a dry and stable hemostatic composition |
| MX345479B (en) | 2010-06-01 | 2017-02-01 | Baxter Int Inc * | Process for making dry and stable hemostatic compositions. |
| CN103096944A (en) | 2010-07-20 | 2013-05-08 | 一般财团法人化学及血清疗法研究所 | Sheet preparation for tissue adhesion |
| DK3243489T3 (en) * | 2011-05-24 | 2021-05-10 | Takeda As | WROLLED COLLAGEN CARRIER |
| RU2013155713A (en) * | 2011-07-06 | 2015-08-20 | Профибрикс Бв | COMPOSITIONS FOR TREATMENT OF THE RAS |
| CN102357259A (en) | 2011-07-28 | 2012-02-22 | 王珊珊 | Bioprotein sponge and preparation method thereof |
| US20130041406A1 (en) * | 2011-08-10 | 2013-02-14 | Brian W. Bear | Surgical staple with localized adjunct coating |
| EP2556842A1 (en) | 2011-08-11 | 2013-02-13 | Bioftalmik, S.L. | Composition in the form of film comprising fibrinogen and a fibrinogen activator and the applications thereof |
| WO2013053759A2 (en) | 2011-10-11 | 2013-04-18 | Baxter International Inc. | Hemostatic compositions |
| KR102135484B1 (en) | 2011-10-11 | 2020-07-20 | 백스터 인터내셔널 인코포레이티드 | Hemostatic compositions |
| SA112330957B1 (en) | 2011-10-27 | 2015-08-09 | باكستر انترناشونال انك. | Hemostatic compositions |
| CA2865349C (en) | 2012-03-06 | 2021-07-06 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| ES2890098T3 (en) | 2012-05-14 | 2022-01-17 | Teijin Ltd | Molding of sheets and hemostatic material |
| PL2854737T3 (en) | 2012-05-24 | 2017-04-28 | Takeda As | Packaging |
| ES2724233T3 (en) | 2012-05-24 | 2019-09-09 | Takeda As | Apparatus and process for providing a rolled collagen carrier |
| CA2874290C (en) | 2012-06-12 | 2020-02-25 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| CN104902974B (en) | 2012-07-06 | 2017-07-28 | 三维矩阵有限公司 | The filling processing method of peptide solution |
| DE102013004420A1 (en) | 2012-08-20 | 2014-02-20 | Alexander Kopp | Support body and method for its production |
| BR112015012985B8 (en) * | 2012-12-07 | 2020-04-14 | Baxter Healthcare Sa | method for preparing a pharmaceutical hemostatic liquid foam, product combination, transient pharmaceutical hemostatic liquid foam, kit for producing a transient pharmaceutical hemostatic liquid foam, and, use of a pharmaceutical preparation |
| KR101401944B1 (en) * | 2012-12-11 | 2014-05-30 | 세원셀론텍(주) | Tissue sealant of collagen and fibrin mixed and method of manufacturing the same |
| US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| US10765774B2 (en) | 2013-07-09 | 2020-09-08 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
| CA2928963C (en) | 2013-12-11 | 2020-10-27 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| CA2939696C (en) | 2014-03-10 | 2023-01-10 | 3-D Matrix, Ltd. | Self-assembling peptide compositions |
| JP6545727B2 (en) | 2014-03-10 | 2019-07-17 | 株式会社スリー・ディー・マトリックス | Spontaneous organization peptides for treating lung air vesicles |
| ES2927887T3 (en) | 2014-03-10 | 2022-11-11 | 3 D Matrix Ltd | Sterilization of peptide compositions |
| CN106999621B (en) | 2014-10-13 | 2020-07-03 | 弗罗桑医疗设备公司 | Dry composition for hemostasis and wound healing |
| US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| EP3316930B1 (en) | 2015-07-03 | 2019-07-31 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| US10814038B2 (en) | 2016-01-06 | 2020-10-27 | 3-D Matrix, Ltd. | Combination compositions |
| CN106267328B (en) * | 2016-09-20 | 2019-04-12 | 安徽思维特生物科技有限公司 | A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel |
| CN106730031A (en) * | 2016-12-30 | 2017-05-31 | 清华大学 | A kind of bionic fiber protein hydrogel beam repaired for spinal cord injury and preparation method thereof |
| CN111712230B (en) | 2017-12-15 | 2024-04-26 | 立美基股份有限公司 | Surfactant peptide nanostructures and their use in drug delivery |
| KR20210008479A (en) | 2018-05-09 | 2021-01-22 | 훼로산 메디칼 디바이스 에이/에스 | How to prepare a hemostatic composition |
| RU2679616C1 (en) * | 2018-07-02 | 2019-02-12 | Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Method for preparing a thrombofibrin clot with growth-stimulating properties |
| JP7481008B2 (en) * | 2018-12-14 | 2024-05-10 | 株式会社ビーエムジー | Two-reaction type sheet-type tissue adhesive reinforcement material |
| CN112225937B (en) * | 2020-10-14 | 2022-11-01 | 中山大学 | Temperature-sensitive macroporous biological hydrogel and preparation method and application thereof |
| CN113117158B (en) * | 2021-03-10 | 2022-07-26 | 复旦大学 | Material for biological functional modification of surface denatured protein and preparation method and application thereof |
| CN114177346B (en) * | 2021-12-24 | 2023-05-26 | 中国人民解放军军事科学院军事医学研究院 | Hemostatic composition and hemostatic patch and application thereof |
| CN114246974B (en) * | 2021-12-24 | 2023-11-03 | 中国人民解放军军事科学院军事医学研究院 | Preparation method of hemostatic patch |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1596789A (en) * | 1968-11-27 | 1970-06-22 | ||
| DE3105624A1 (en) * | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
| BR8102435A (en) * | 1981-04-15 | 1982-11-30 | Campos Vidal Benedicto | MICROFIBRILLARY AND MICRO CRYSTALLINE COLLAGEN FOR MEDICINE AND PHARMACY APPLICATION |
| DE3214337C2 (en) * | 1982-04-19 | 1984-04-26 | Serapharm - Michael Stroetmann, 4400 Münster | Resorbable flat material for sealing and healing wounds and processes for their manufacture |
| US4626286A (en) | 1983-10-31 | 1986-12-02 | Schmid Laboratories, Inc. | Collagen gel and the process of making said gel |
| US5318524A (en) * | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
| FR2668936B1 (en) * | 1990-11-09 | 1993-01-15 | Eberlin Jean Luc | GRAFT BASED ON COLLAGEN AND FIBRIN GLUE FOR OSTEO-CARTILAGINOUS RECONSTRUCTION AND ITS PREPARATION METHOD. |
| WO1992017209A1 (en) * | 1991-04-08 | 1992-10-15 | Sumitomo Pharmaceuticals Company, Limited | Porous solid preparation containing physiologically active protein substance |
| US6177126B1 (en) * | 1993-03-31 | 2001-01-23 | Nycomed Arzneimittel Gmbh | Process for the production of a material for sealing and healing wounds |
| AT410754B (en) * | 1993-03-31 | 2003-07-25 | Nycomed Austria Gmbh | DEVICE FOR EVENLY APPLYING A SUSPENSION TO A COLLAGE CARRIER |
| JPH0759812A (en) * | 1993-08-27 | 1995-03-07 | Koken Co Ltd | Wound cover material and its production |
| WO1996007728A1 (en) * | 1994-09-02 | 1996-03-14 | New York Blood Center, Inc. | Production and secretion of recombinant fibrinogen by yeast |
| WO1997028832A1 (en) * | 1996-02-06 | 1997-08-14 | New Generation Medical Corporation | Composition for sealing wounds |
| DE69724243T2 (en) * | 1996-04-04 | 2004-06-17 | Baxter Ag | Hemostatic sponge based on collagen |
| WO1999059647A1 (en) * | 1998-05-19 | 1999-11-25 | The American National Red Cross | Hemostatic sandwich bandage |
| EP1073485B1 (en) * | 1998-05-01 | 2003-03-19 | ZymoGenetics, Inc. | Fully recombinant tissue sealant compositions |
| CA2339575A1 (en) * | 1998-08-10 | 2000-02-24 | James W. Polarek | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
| KR100804434B1 (en) * | 1998-12-23 | 2008-02-20 | 체에스엘 베링 게엠베하 | Fibrin-based glue granulate and corresponding production method |
| DE19922078A1 (en) * | 1999-05-15 | 2000-11-23 | Weitzel Kage Doris | Tissue construct for transplant surgery |
-
2002
- 2002-01-25 WO PCT/IB2002/001453 patent/WO2002058749A2/en active IP Right Grant
- 2002-01-25 AT AT02718481T patent/ATE310044T1/en active
- 2002-01-25 NZ NZ527167A patent/NZ527167A/en not_active IP Right Cessation
- 2002-01-25 AU AU2002249528A patent/AU2002249528B2/en not_active Expired
- 2002-01-25 MX MXPA03006687A patent/MXPA03006687A/en active IP Right Grant
- 2002-01-25 SK SK1034-2003A patent/SK10342003A3/en not_active Application Discontinuation
- 2002-01-25 PL PL363274A patent/PL205181B1/en unknown
- 2002-01-25 KR KR1020037009899A patent/KR100830294B1/en active IP Right Grant
- 2002-01-25 BR BRPI0206708A patent/BRPI0206708B8/en not_active IP Right Cessation
- 2002-01-25 NZ NZ527165A patent/NZ527165A/en not_active IP Right Cessation
- 2002-01-25 JP JP2002559084A patent/JP4535678B2/en not_active Expired - Lifetime
- 2002-01-25 KR KR1020037009893A patent/KR100847417B1/en active IP Right Grant
- 2002-01-25 AR ARP020100259A patent/AR032400A1/en active IP Right Grant
- 2002-01-25 EA EA200300821A patent/EA005697B1/en not_active IP Right Cessation
- 2002-01-25 BR BRPI0206705A patent/BRPI0206705B8/en not_active IP Right Cessation
- 2002-01-25 AR ARP020100258A patent/AR032517A1/en active IP Right Grant
- 2002-01-25 DE DE60203364T patent/DE60203364T2/en not_active Expired - Lifetime
- 2002-01-25 EE EEP200300349A patent/EE05587B1/en unknown
- 2002-01-25 ME MEP-2009-24A patent/ME00587B/en unknown
- 2002-01-25 SK SK1035-2003A patent/SK288120B6/en not_active IP Right Cessation
- 2002-01-25 UY UY27136A patent/UY27136A1/en not_active IP Right Cessation
- 2002-01-25 CA CA002434964A patent/CA2434964C/en not_active Expired - Lifetime
- 2002-01-25 RS YUP-670/03A patent/RS50866B/en unknown
- 2002-01-25 CN CNB02804097XA patent/CN1246047C/en not_active Expired - Fee Related
- 2002-01-25 EA EA200300822A patent/EA006686B1/en not_active IP Right Cessation
- 2002-01-25 HU HU0303893A patent/HU228810B1/en unknown
- 2002-01-25 DK DK02724554T patent/DK1343542T3/en active
- 2002-01-25 IL IL15709702A patent/IL157097A0/en unknown
- 2002-01-25 AU AU2002255220A patent/AU2002255220B2/en active Active
- 2002-01-25 EP EP02734886A patent/EP1359947A2/en not_active Ceased
- 2002-01-25 JP JP2002559083A patent/JP2004521115A/en active Pending
- 2002-01-25 CZ CZ2003-2198A patent/CZ305120B6/en not_active IP Right Cessation
- 2002-01-25 EE EEP200300341A patent/EE05685B1/en not_active IP Right Cessation
- 2002-01-25 SI SI200230138T patent/SI1343542T1/en unknown
- 2002-01-25 PL PL366932A patent/PL206197B1/en unknown
- 2002-01-25 TW TW091101277A patent/TWI237573B/en not_active IP Right Cessation
- 2002-01-25 EP EP02724554A patent/EP1343542B1/en not_active Expired - Lifetime
- 2002-01-25 NZ NZ527166A patent/NZ527166A/en not_active IP Right Cessation
- 2002-01-25 EP EP02718481A patent/EP1368419B1/en not_active Expired - Lifetime
- 2002-01-25 AU AU2002307809A patent/AU2002307809B2/en not_active Expired
- 2002-01-25 PL PL363275A patent/PL206194B1/en unknown
- 2002-01-25 WO PCT/IB2002/001454 patent/WO2002058750A2/en active IP Right Grant
- 2002-01-25 CN CNB028040953A patent/CN1290907C/en not_active Expired - Lifetime
- 2002-01-25 UA UA2003087939A patent/UA73028C2/en unknown
- 2002-01-25 CA CA002435159A patent/CA2435159C/en not_active Expired - Lifetime
- 2002-01-25 SK SK1036-2003A patent/SK287874B6/en not_active IP Right Cessation
- 2002-01-25 CZ CZ20032199A patent/CZ20032199A3/en unknown
- 2002-01-25 MX MXPA03006688A patent/MXPA03006688A/en active IP Right Grant
- 2002-01-25 DE DE60207389T patent/DE60207389T2/en not_active Expired - Lifetime
- 2002-01-25 ES ES02724554T patent/ES2238569T3/en not_active Expired - Lifetime
- 2002-01-25 SI SI200230251T patent/SI1368419T1/en unknown
- 2002-01-25 HU HU0400768A patent/HUP0400768A3/en unknown
- 2002-01-25 JP JP2002570628A patent/JP4104462B2/en not_active Expired - Lifetime
- 2002-01-25 ES ES02718481T patent/ES2253523T3/en not_active Expired - Lifetime
- 2002-01-25 EA EA200300823A patent/EA006700B1/en not_active IP Right Cessation
- 2002-01-25 AR ARP020100260A patent/AR032800A1/en not_active Application Discontinuation
- 2002-01-25 CA CA2435425A patent/CA2435425C/en not_active Expired - Lifetime
- 2002-01-25 IL IL15709602A patent/IL157096A0/en active IP Right Grant
- 2002-01-25 TW TW091101272A patent/TWI255726B/en not_active IP Right Cessation
- 2002-01-25 EE EEP200300348A patent/EE05678B1/en unknown
- 2002-01-25 AT AT02724554T patent/ATE291445T1/en active
- 2002-01-25 PT PT02724554T patent/PT1343542E/en unknown
- 2002-01-25 WO PCT/IB2002/001452 patent/WO2002070594A2/en active IP Right Grant
- 2002-01-25 DK DK02718481T patent/DK1368419T3/en active
- 2002-01-25 IL IL15709502A patent/IL157095A0/en unknown
- 2002-01-25 CZ CZ2003-2197A patent/CZ304357B6/en not_active IP Right Cessation
- 2002-01-25 MX MXPA03006689A patent/MXPA03006689A/en active IP Right Grant
- 2002-01-25 EP EP05075501A patent/EP1547626A3/en not_active Withdrawn
- 2002-01-25 CN CNB028040961A patent/CN1264578C/en not_active Expired - Lifetime
- 2002-01-25 EA EA200401463A patent/EA006540B1/en not_active IP Right Cessation
- 2002-01-25 BR BRPI0206709A patent/BRPI0206709B8/en not_active IP Right Cessation
- 2002-01-25 HU HU0303896A patent/HU227987B1/en unknown
- 2002-01-26 EG EG2002010097A patent/EG26417A/en active
- 2002-01-26 EG EG20020095A patent/EG24589A/en active
-
2003
- 2003-07-22 NO NO20033296A patent/NO327386B1/en not_active IP Right Cessation
- 2003-07-22 NO NO20033295A patent/NO332462B1/en not_active IP Right Cessation
- 2003-07-22 NO NO20033297A patent/NO20033297L/en not_active Application Discontinuation
- 2003-07-23 CR CR7034A patent/CR7034A/en unknown
- 2003-07-24 IL IL157095A patent/IL157095A/en active IP Right Grant
- 2003-07-24 IL IL157096A patent/IL157096A/en unknown
- 2003-07-24 IL IL157097A patent/IL157097A/en not_active IP Right Cessation
- 2003-07-24 IS IS6885A patent/IS6885A/en unknown
- 2003-08-12 HR HR20030648A patent/HRP20030648B1/en not_active IP Right Cessation
- 2003-08-21 BG BG108121A patent/BG66420B1/en unknown
- 2003-08-21 BG BG108122A patent/BG66343B1/en unknown
- 2003-08-21 BG BG108123A patent/BG66439B1/en unknown
-
2004
- 2004-02-16 HK HK04101068A patent/HK1058319A1/en not_active IP Right Cessation
- 2004-02-16 HK HK04101070A patent/HK1058371A1/en not_active IP Right Cessation
-
2007
- 2007-03-01 JP JP2007051088A patent/JP2007190399A/en active Pending
-
2015
- 2015-10-21 CL CL2015003111A patent/CL2015003111A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1368419B1 (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
| US7098315B2 (en) | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
| AU2002249528A1 (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
| EP1259269B1 (en) | Agent for the treatment of wounds | |
| WO1999064655A1 (en) | Collagen material and process for producing the same | |
| EP3122300A1 (en) | A ready to use biodegradable and biocompatible device and a method of preparation thereof | |
| WO1989008465A1 (en) | Medical material permitting cells to enter thereinto and artificial skin | |
| CN110639050A (en) | Silk fibroin nanofiber and preparation method of silver-loaded antibacterial dressing based on silk fibroin nanofiber | |
| CN101785873A (en) | Biocompatible bleed-stopping and bone healing promoting material and preparation method thereof | |
| Silverstein et al. | Collagen fibers as a fleece hemostatic agent | |
| JP2000060956A (en) | Collagen material and manufacture thereof | |
| WO2001066159A1 (en) | Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such | |
| US5138030A (en) | Process for extracting type I collagen form an avian source, and applications therefor | |
| ZA200305591B (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge. | |
| EP1325060B1 (en) | Soybean-based thermoplastics as biomaterials | |
| CN115227878B (en) | Silver-loaded type-I collagen composite material and preparation method and application thereof | |
| Koller et al. | Biocompatibility studies of modified collagen/Hyaluronan membranes after implantation | |
| CN118403207A (en) | Injectable fibrin glue composite system formed by crosslinking genipin with silk fibroin and preparation method thereof | |
| CN117547657A (en) | Biological adhesive film and preparation method thereof | |
| JP2016501270A (en) | Collagen powder |